OBJECTIVE. Noonan syndrome is a clinically homogeneous but genetically heterogeneous condition. Type 1 Noonan syndrome is defined by the presence of a mutation in the PTPN11 gene, which is found in ϳ40% of the cases. Phenotype descriptions and cardiac defects from cohorts with Noonan syndrome were delineated in the "pregenomic era." We report the heart defects and links to gene dysfunction in cardiac development in a large cohort of patients with type 1 Noonan syndrome.
N OONAN SYNDROME (NS) is an autosomal dominant multiple congenital anomalies syndrome that is characterized by minor facial anomalies (hypertelorism, downward slant of the palpebral fissures with ptosis, and low-set posteriorly angulated ears), short stature, congenital heart defects (CHDs), and variable learning disabilities. With an estimated incidence of 1 in 2000, 1 NS turned out to be 1 of the most common genetic condition in pediatrics and the second most common syndromal form of CHD, after trisomy 21. 2 Type 1 NS corresponds to the causally homogeneous subgroup of patients who have NS and are molecularly defined by the presence of a mutation in the PTPN11 gene. Mutations in PTPN11 are responsible for ϳ40% of the cases of NS and for Ͼ95% of patients with LEOPARD syndrome (lentigines, EKG anomalies, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, deafness). The penetrance of the mutations of PTPN11 is 100%, but their expressivity is variable even within families. Very recently, mutations in KRAS 3 and SOS1 4, 5 were shown in, respectively, Ͻ5% and 15% of PTPN11-negative patients with NS. PTPN11, SOS1, and KRAS are part of the RAS signaling pathway. The causative gene(s) remains to be found for roughly half of patients with NS.
A broad spectrum of cardiac phenotypes has been recognized in NS. Pulmonary valve stenosis (PVS), hypertrophic cardiomyopathy (HCM) and atrial septal defect of ostium secundum type (ASD-OS) are the most common defects in NS, but ventricular septal defect (VSD), peripheral pulmonary stenosis, atrioventricular canal, aortic stenosis, mitral regurgitation, aortic coarctation, and coronary anomalies can also be seen in NS. Previous studies of cohorts of patients with NS suggested that the prevalence of specific types of CHD was different in type 1 NS and in NS without PTPN11 mutation. [6] [7] [8] [9] [10] [11] We report the cardiac anomalies in a large cohort of patients with type 1 NS to delineate the spectrum of cardiac defects that are caused by PTPN11 mutations and better understand the role of PTPN11 in heart development.
METHODS
Patients with NS or LEOPARD syndrome were recruited through a multicenter network of clinical geneticists from France, Switzerland, and Belgium for molecular analysis of the PTPN11 gene. The patients were entered systematically in the study, on the basis of the order by which samples arrived in the laboratory for diagnosis. Checklists were systematically sent to referring geneticists independently and before completion of the DNA screening. Call for supplementary data was not based on the identification (or not) of a mutation. Specific cardiologic data were derived from records of transthoracic echocardiography and, when available, from cardiac catheterization and/or heart surgery. Because the data were mainly retrospective, distinction between PVS with normal valves and pulmonary valve dysplasia was hampered by the impossibility to check retrospectively for the presence of valvular dysplasia in patients for whom only pulmonary stenosis was mentioned. For this reason, we decided to merge the 2 anomalies under the term PVS.
Mutation screening focused on hot-spot locations in the PTPN11 gene, which covered 98% of identified mutations. [6] [7] [8] [9] Exons 2, 3, 4, 7, 8, 12 , and 13 of the PTPN11 gene and their intron-exon boundaries were sequenced on both strands from genomic DNA for each patient on an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). Mutations were identified using ABI PRISM SeqScape 2.0 (Applied Biosystems) by comparison with the reference sequence for genomic and complementary DNA sequence (GenBank accession Nos. NT009775.14 and NM002834).
Statistical analysis for qualitative data and comparison used 2 and exact Fisher test. Significance was determined as P Ͻ .05. Informed consent was obtained for inclusion and DNA screening. The ethics committee of AP-HP Bichat University Hospital (Paris, France) approved the study.
RESULTS
A total of 291 patients with NS or LEOPARD syndrome were initially enrolled in the study. The 19 patients who presented with café -au-lait spots and/or lentigines were found to share a small number of specific mutations. Because their clinical and molecular diagnosis was LEOPARD syndrome, they were studied and published separately. 12 The final cohort of patients with NS comprises 149 boys and 123 girls. The mean age in the cohort is 7 years for the groups both with and without mutation (lower quartile: 2 years; upper quartile: 13 years).
A mutation in the PTPN11 gene was identified in 104 (38.25%) patients. Table 1 summarizes the cardiologic findings in patients. The c.922A3 G (p.N308D) nucleotide substitution represents the most prevalent mutation (18.25%) in our patients. Table 2 presents the spectrum of CHD by functional domain, by exon, and, specifically, by those observed with the p.N308D mutation.
Among patients with a mutation, the apparent rate of heart defect is 85%. Because the selection criteria for offering molecular testing were clinically based and potentially biased toward overrepresentation of CHD-bearing patients, the true penetrance of CHDs in type 1 NS can nevertheless not be established objectively. The most prevalent CHD in type 1 NS are PVS (60%), ASD-OS (25%), and stenosis of the peripheral pulmonary arteries (in at least 15.4%). PVS and ASD-OS are significantly associated with the presence of a mutation (P Ͻ .01), and coarctation of aorta and HCM are associated with the absence of mutation. VSD and most left-sided heart defects show a trend toward overrepresentation in the group without a mutation. Comparison with previously reported series of genotyped NS is difficult. We summa-rized the published data on CHDs in type 1 NS in Table  3 and compared the relative incidence of major CHDs in type 1 NS versus the general population based, for example, on prevalence data from Eurocat Database registries from European Western countries and/or Italian and/or Iceland databases (Table 4) .
DISCUSSION
PTPN11 is a gene that is located on chromosome band 12q24.1 and encodes the nonreceptor protein tyrosine phosphatase SHP-2. The protein contains a phosphatase domain (PTP domain) and 2 amino-terminal SH2 domains (N-SH2 and C-SH2) that selectively bind to short amino acid motifs that contain a phosphotyrosyl residue. These SH2 domains promote SHP-2 association with cell surface receptors and cell adhesion molecules' and modulate the cells' responses to extracellular signals by regulating the phosphotyrosine content of specific intracellular proteins. More specific, SHP-2 functions as an intracellular enhancer of signal transduction for several growth factors, hormones, and cytokine receptors that are involved in the RAS/MAPK (rat sarcoma viral oncogene homolog/mitogen-activated protein kinase) signaling pathway, although its precise role in the pathway, as inhibitor of RAS inactivation by GAP (guanosinetriphosphatase-activating protein) proteins or as enhancer of the kinase cascade beyond RAS activation, remains elusive. 13 The N-SH2 domain is a conformational switch: it either binds to and inhibits the PTP domain or binds phosphotyrosine proteins and allows the PTP catalytic domain to bind to specific phosphoproteins residues and hydrolyze them. 8 Almost all reported mutations so far are missense exon changes, except for a unique in-frame 3-bp deletion. 14 Almost all NS mutations are gain-offunction mutations that seem to alter N-SH2-PTP interaction, turning protein into a constitutionally active state. [15] [16] [17] Some of them might further affect SH2 domain-phosphopeptide affinity and/or substrate specificity. 18 Mutations cluster in 7 exons (2, 3, 4, 7, 8, 12, and 13) . Those exons encode the interacting portions of SH2 and the PTP domains or the hinges segment binding the 3 domains. Exons 3 and 8 harbor 80% of the mutations. A single mutation (c.922A3 G-p.N308D-exon 8) is present in ϳ20% of patients. Contrasting with NS mutations, LEOPARD syndrome mutants are catalytically defective and act as dominant negative mutations. 16, 19, 20 The spectrum of CHDs has been widely described in The last column summarizes the CHD associated with the single common N308D mutation located on exon 8.
NS before the era of PTPN11 gene identification: PVS, ASD-OS, VSD, Ebstein anomaly, and coarctation of aorta were the most common heart defects encountered in patients with NS, as well as HCM. Since the discovery of PTPN11 involvement in type 1 NS, 6 small cohorts of patients have been reported from Europe and Asia. [6] [7] [8] [9] [10] [11] The spectrum of CHD in type 1 NS cannot be drawn easily from these cohorts ( Table 3 ). In the genotype/phenotype cohort study by Tartaglia et al, 6 only PVS, ASD-OS, and HCM were considered. PVS was present in 70.6% of the group with mutation and in 46.2% of the group without mutation (P Ͻ .01), whereas HCM was more prevalent in patients without a mutation (26% vs 5.9%; P Ͻ 0,01). The other CHDs were not reported and a "PTPN11-negative" group was not described. In a study of 96 patients with NS, Musante et al 8 found a mutation rate of 29%. PVS was present in 60%; no HCM was identified among PTPN11-positive patients. There was no information on cardiac findings in the group without mutation, and only PVS, septal defects (of all types), and HCM were reported. The cardiac defects in the PTPN11-positive group were limited to the presence (or absence) of PVS, ASD-OS, VSD, and HCM. Sarkozy et al 7 reported 73 patients with NS or LS and identified a mutation in 37% of the cases. Among patients with a mutation, PVS, HCM, partial AVC, and ASD-OS were the most common anomalies. No coarctation of aorta, tetralogy of Fallot, or VSD was observed. A trend for ASD-OS to be correlated with exon 3 mutations was suggested. All mutations in the N-SH2 domain were associated with the presence of a heart defect, whereas in 70%, the mutations occurred in the PTP domain. Zenker et al 9 reported 57 children with NS. The mutation rate was 60%. PVS was noted in 88% and HCM was noted in 3% of PTPN11-positive patients. The cardiac findings in the group without mutation were not given. Among 45 cases, Yoshida et al 10 detected PVS in 55% of patients with mutation. As in Tartaglia's and Musante's studies, only PVS, HCM, or ASD-OS was recorded. In the most recent study, 11 only PVS, HCM, ASD-OS were described separately.
Preselection criteria may explain differences between our study and the previous ones. Tartaglia et al 6 included patients with clinical phenotype "evocative" of NS and PVS or HCM and/or pectus deformity or electrocardio- gram anomaly, whereas Zenker et al 9 used a combination of 2 of 3 criteria: typical heart defect (PVS or HCM), typical craniofacial morphology, and pterygium colli. The last suggested that his higher mutation rate was attributable to more stringent and rigorous inclusion criteria. These criteria may bias to selecting patients with the 2 most prevalent defects. No data have been published on the incidence of peripheral pulmonary stenosis in NS type 1. Physiologically, transient peripheral pulmonary stenosis is encountered in normal newborns (during transition from fetal to postnatal). Its incidence in our series is unlikely to reflect a physiologic transient state.
Comparison of patients with and without mutation is presented in Table 1 . PVS was identified in 59.6% among mutation carriers (62 of 104) and 31.5% in the noncarrier group (53 of 168), ASD-OS respectively in 25% (26 of 104) and 13% (22 of 168), and stenosis of the peripheral pulmonary arteries in 15.4% (16 of 104) and 10.1% (17 of 168). Left-sided involvement was associated with absence of an identified PTPN11 mutation: mitral insufficiency in 4.8% (5 of 104) vs 7.1% (12 of 168), aortic stenosis in 1.9% (2 of 104) vs 4.7% (8 of 168), and coarctation of aorta in 0.96% (1 of 104) vs 5.95% (10 of 168; P Ͻ .01). Finally, presence of VSD occurred in 6.75% (7 of 104) vs 13.7% (23 of 168; P Ͻ .001).
Genotype-phenotype correlations within type 1 NS have been briefly addressed. In our cohort, nucleotide substitutions occurred in 44 (42.30%) in the N-SHP domain (exons 2 and 3), 5 (4.8%) in the C-SHP domain, 3 (2.9%) at the N-SHP/C-SHP hinge region, and 52 (50%) in the PTP domain. Exon 2 mutations were identified in Ͻ1%. Exon 3 mutations occurred in half of the cases; PVS was associated in 46% (29 of 62) of the cases. Exons 4 and 7 mutations were observed in 4.8% and 5.8%, respectively. Exon 8 mutations occurred in 26%. The N308D substitution has an incidence of 18.26% (19 of 104) . PVS is the more common cardiac defect associated with exon 8 mutations, accounting for 58% (11 of 19) of CHD. Mutations in exon 13 account for 18.30%, 55% (10 of 19) being PVS. In Table 4 , we compared the frequencies of CHD in patients with NS with their frequencies in the general population, based on registries of congenital anomalies, and computed relative risks (when possible). This relative risk varies widely, from 0.22 for D-transposition of the great arteries to 35.6 for mitral insufficiency. The spectrum of CHD that is observed with PTPN11 mutations points to a crucial role for this gene in the normal pattern of right cardiac development and anatomy. Left-sided heart malformations are more prevalent in PTPN11-negative patients.
The function of PTPN11 gene during heart embryogenesis remains to be elucidated. Ptpn11, the mouse ortholog of the human PTPN11, is required during early mouse development for gastrulation. A mouse that carries the D61G mutation has been produced and recapitulates NS. 26 In a mouse model, Chen et al 27 found that normal epithelial growth factor receptor (Egfr) signaling pathway necessitates interaction of Egfr with Shp2. The Egfr pathway is necessary to permit semilunar valve development. Despite their involvement in NS, expression of PTPN11 does not seem to occur in atrioventricular valves. 18, 27 Mice that bear homozygous Egfr mutations show electrocardiographic anomalies, aortic stenosis, and regurgitation. In the chick embryo, the hyperproliferative effect of an expressing Shp2 bearing a type 1 NS mutation Q79R on mesenchymal cells in valve primordia was shown to be mediated by extracellular signal-regulated kinase 1/2 activation through the RAS/ MAPK pathway. The effect was similarly obtained when transfecting the gene for a constitutively active MEK-1, a downstream molecule that regulates ERK (extracellular signal-regulated kinase) phosphorylation, the mutations of which result in cardiofaciocutaneous syndrome. 28 Finally, PTPN11 may interfere with calcium/ calcineurin/nuclear factor of activated T cell (NFAT) signaling. Calcineurin is a calmodulin-dependent, calcium-activated serine/threonine-specific protein phosphatase. On activation by Ca 2ϩ , calcineurin dephosphorylates the NFAT transcription factor, leading to its nuclear translocation and activation. In mice, NFAT activation represses VEGF (vascular endothelial growth factor) expression in the myocardium underlying the site of prospective valve formation, which is essential for endocardial cells to transform into mesenchymal cells and, later, for direct valvular elongation and refinement. 29 The calcium/calcineurin/NFAT signal transduction pathway has been implicated in a variety of developmental processes, including in cardiomyocyte maturation, heart valve formation, vascular development, 30, 31 and cardiomyocyte hypertrophy. 32 It has been shown that gain-of-function mutants of SHP-2 enhanced fibroblast growth factor-2-mediated Ca 2ϩ oscillations in fibroblasts, spontaneous Ca 2ϩ oscillations in cardiomyocytes, and reduced nuclear translocation and transcriptional activity of NFAT, pointing to a possible link between the calcium/calcineurin/NFAT pathway and PTPN11. 33 It is interesting that PTPN11 is not involved in nonsyndromic atrioventricular septal defects and coarctation of the aorta 34 or in nonsyndromic HCM. 35 
CONCLUSIONS
Our study of CHDs in type 1 NS illustrates the wide spectrum of developmental anomalies that result from dysregulation of the RAS/MAPK signaling pathway and the difficulty of correlating molecular anomalies with the occurrence of a type of CHD.
